Immunologic tumor therapies aim to prolong patient survival mainly by inducing cytotoxic CD8+ T cell responses to a limited number of tumor epitopes. We have demonstrated in a murine melanoma model the independency of prolonged survival from the strength of induced CD8+ T cell responses. We speculate that a major part of this effect is due to the protection from tumor metastases formation. We would now like to investigate the underlying mechanisms to provide hints for tumor therapy improvement.
Department of Dermatology